Received Jan 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | U7449AB | OT / RA |
expired dose of MENQUADFI was administered to a patient, with no reported adverse event; Initial information received on 12-Jan-2026 regarding an unsolicited valid non-serious case received from a physician. This case involves Adult female patient of unknown age and whom expired dose of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] was administered with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Hepatitis b vaccine (Hepatitis b) for Immunisation. On 10-Jan-2026, the patient received expired dose a 0.5 ml (Dose 1) of suspect Meningococcal A-C-Y-W135 (T CONJ) Vaccine of lot U7449AB and expiry date: 23Sep-2024 frequency: once and strength: standard via intramuscular route in the right deltoid for immunization with no reported adverse event (expired product administered) (latency: on same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Hepatitis b